Roles of Apolipoproteins B and E in the Cellular Binding of Very Low Density Lipoproteins

E. S. Krul, M. J. Tikkanen, T. G. Cole, J. M. Davie, and G. Schonfeld

Lipid Research Center, Departments of Preventive Medicine, Medicine, and Microbiology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110

Abstract

Apolipoproteins B and E both interact with cellular low density lipoprotein (LDL) apolipoprotein B and E (apo B,E)-receptors, and very low density lipoproteins (VLDL) contain both apo B and apo E. Our aim was to study the relative importance of apo B and apo E in the binding of VLDL subfractions to cells. Two monoclonal anti-LDL-apo B antibodies (464B1B3 and 464B1B6, 2a and 2b, respectively) and two anti-apo E antibodies (1506 A1.4 and 1907 F6.4) were used to inhibit lipoprotein-cell interactions.

In confirmation of previous findings, the binding and degradation of 125I-LDL by human fibroblasts were inhibited ~90% by antibodies 2a or 2b or the antigen-binding fragments of 2a, whereas the cellular processing of 125I-VLDL1 (S20-60), 125I-VLDL2 (S60-120), and 125I-VLDL3 (S7>120) were inhibited by only ~50%, ~25%, and <10%, respectively. The VLDL1-3 and LDL-dependent intracellular esterification of cholesterol with [3H]oleate were inhibited to a similar extent. Other monoclonal anti-human apo B antibodies inhibited lipoprotein-cell interactions much less effectively and nonimmune IgG isolated from mouse serum did not inhibit at all. 20-fold excesses of LDL produced about the same patterns of inhibition of degradation of 125I-VLDL1-3 and LDL by cells as did antibodies 2a and 2b, whereas homologous unlabeled VLDL1-3 in like amounts inhibited the matched 125I-VLDL1 subfraction more effectively. Two anti-apo E monoclonal antibodies and a polyclonal anti-apo E antibody inhibited cell-mediated degradation of and lipoprotein-dependent cholesterol esterification by VLDL1 but not VLDL3 or LDL. The results suggest that receptor recognition sites on apo E in preference to sites on apo B mediate the cellular binding of hypertriglyceridemic VLDL1. However, the proportion of particles bound via apo B seems to increase as VLDL decreases in size toward LDL, and virtually all of LDL binding is mediated by apo B.

Introduction

Very low density lipoproteins (VLDL) isolated from normal plasma (1, 2). Density gradient ultracentrifugation can be used to subfractionate VDL (3, 4), and it seems that differences between the cell reactivities of normal and hypertriglyceridemic (HTG) VLDL are most readily apparent when the largest particles, S7>100, or VLDL1 fractions are compared (5). The cellular uptake of the VLDL1 fraction, which contains both apo B and apo E (6-8), is mediated by the same apo B,E receptor on fibroblasts (9-12) that recognizes low density lipoprotein (LDL) (13), which contains only apo B (13-15). Therefore, it was of great interest when Gianturco et al. (16) recently reported that the recognition of HTG-VLDL by fibroblasts occurred via apo E rather than apo B. Gianturco et al. (16) reached this conclusion by showing that thrombin digestion of VLDL abolished its cellular recognition. Concomitantly, VLDL1-apo E was cleaved into two major 22,000- and 12,000-mol wt peptides. Similar treatment of LDL had no effect on its recognition by cells. Furthermore, addition of intact apo E to thrombin-treated VLDL1 restored its capacity to interact with cells, and addition of apo E to VLDL1 isolated from normolipidemic subjects increased its recognition by cells.

We also have been interested in the interaction of apo B-containing lipoproteins with cultured cells (17-19), and have developed mouse monoclonal anti-human LDL antibodies as probes of lipoprotein-apo B structure and as inhibitors of lipoprotein-cell interactions. In these experiments, the monoclonal IgG antibodies, 2a and 2b, have been reported with the following characteristics: a) both antibodies 2a and 2b are phosphatidylcholine vesicles does not react with antibodies 2a and 2b (G. Schonfeld, unpublished observations). Anti-human apo E monoclonal antibodies have also been developed in this laboratory. Two of these antibodies, 1506 A1.4 and 1907 F6.4, were used in the present study in an attempt to block apo E-mediated cell binding.

In the experiments to be reported, the apo B and apo E antibodies were used to inhibit the cell recognition of VLDL subfractions and LDL, to assess the roles of apo B and apo E.

Received for publication 2 September 1983 and in revised form 15 October 1984.

1. Abbreviations used in this paper: apo B, apolipoprotein B; apo E, apolipoprotein E; Fab, antigen-binding fragment; HTG, hypertriglyceridemic; TMU, tetramethylurea.

in the binding of these lipoproteins to fibroblasts. We conclude that apo B plays a very small role compared with apo E in the cellular binding of the largest VLDL fractions, VLDL₁, but that the binding of progressively increasing proportions of the smaller and more dense VLDL fractions is mediated by apo B and not apo E, and that nearly all of LDL is recognized via apo B.

**Methods**

**Lipoprotein donors.** Lipoproteins of six subjects with hypertriglyceridemia and six normal controls were studied. Clinical characteristics are given in Table I. Lipoprotein lipid values are representative of those obtained for each subject at diagnosis. Patients were not taking medications and none had visible chylomicronemia.

**Isolation of lipoproteins.** Blood collected in 0.1% EDTA was obtained from subjects after 12–14 h of fasting. After separation of cells by centrifugation, 10 μM phenylmethylsulfonyl fluoride, 50 μg/l chloramphenicol and 50 μg/l gentamycin were added to the plasma (16, 21). VLDL was immediately isolated by ultracentrifugation at d = 1.006. LDL was isolated between the densities of 1.019 and 1.050 (22). Two ultracentrifugations were carried out at each density. VLDL density subfractions were isolated from VLDL that had been centrifuged only once, by zonal ultracentrifugation using a linear density gradient of 1.00–1.15 g/ml (17, 23). The fastest floating fraction (S120–400) was designated fraction VLDL₁; the S60–120 fraction, VLDL₂; and S20–60 fraction, VLDL₃. On occasion, VLDL fractions were obtained by ultracentrifugation in a salt gradient formed in an SW40 swinging bucket rotor (3). After dialysis against 0.15 M sodium chloride and 1 mM EDTA (pH 8.2), the lipoproteins were concentrated by dry analysis (Aquacide II; Calbiochem-Behring Corp., American Hoochst Corp., San Diego, CA), dialyzed against EDTA-saline, filtered through 0.45-μm filters (Acrodisc; Gelman Sciences, Inc., Ann Arbor, MI), and stored in EDTA-saline containing the above mentioned concentrations of antibacterial agents at 4°C.

The purities of the isolated VLDL and LDL preparations were assessed by 3–10% or 3–20% sodium dodecyl sulfate polyacrylamide gradient gel electrophoresis of the individual samples (24). VLDL apo B/E ratios were calculated from gels in some experiments. In LDL, three bands corresponding to apo B-100, B-74, and B-26 (8) were found by Coomassie Blue staining, but none of the LDL samples contained detectable amounts of B-48, serum albumin, or non-apo B apolipoproteins (21). The HTG-VLDL preparations used in the studies reported here contained apo B-100, trace amounts of apo B-48 and B-26 (Fig. 1), apo E, and apolipoprotein C. The apo B contents of the VLDL subfractions and LDL were determined by tetramethylurea (TMU) precipitation (8). Apo E contents were quantitated by radioimmunossay (RIA) after pretreatment of the VLDL with 6 M urea (25). Total protein contents were measured by modifications of the method of Lowry et al. (26, 27).

**Preparation of purified antibodies and Fab fragments.** Affinity purified human apo B monoclonal antibodies and Fab fragments were prepared as previously described (18). The purity of the Fab fragments was checked by sodium dodecyl sulfate gel electrophoresis in the presence of 1% 2-mercaptoethanol (100°C for 2 min), which yielded two bands of 26,500 and 25,000 apparent molecular weight. The anti-apo B antibodies used in the present study are 464B₆B₇ (2a) and 464B₂₈ (2b), which inhibit binding of LDL to receptors and also define closely related but not identical epitopes 2a and 2b. Antibodies 457C₁D₁ (1a), and 467D₃D₅ (6), which do not inhibit LDL binding and define two other spatially independent epitopes called 1a and 6, were also used as controls.

Monoclonal antibodies were raised against human apo E. The details of their preparation are described elsewhere (Krul, E. S., M. J. Tikkanen, and G. Schonfeld, manuscript in preparation). The anti-apo E monoclonal IgG fraction of ascitic fluid was purified by chromatography on either DEAE Affi-Gel Blue (Bio-Rad Laboratories, Richmond, CA) (28) or Protein-A Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) (29). The apo E antibodies used in the present study are 1506 A1, 1907 F6.4, and 1363 C3A10, and are all of the IgG1 subclass. Six IgM antibodies were also used (827, 1356, and 1366 series).

Polyclonal anti-human apo E antiserum (R224-3) was produced in rabbits (25) and the IgG was purified by ion exchange chromatography on cellulose (DE52; Whatman Chemical Separation, Inc., Clifton, NJ). Nonimmune immunoglobulins were isolated from nonimmunized mouse serum by (NH₄)₂SO₄ precipitation (20–40% of saturation), followed by chromatography on Protein-A Sepharose (29).

**125I-labeling of lipoproteins and antibodies.** VLDL fractions and LDL used in the cell assays were 125I-labeled to a specific activity of ~100 cpm/ng using the iodine monochloride method (30, 31). >90% of the 125I-lipoproteins were precipitable by 10% TCA. The lipid solvent (chloroform/methanol, 2:1 vol/vol) extractable counts for 125I-VLDL were 9–17%, and for 125I-LDL, were 7–9%.

**Table I. Lipoprotein Donors**

<table>
<thead>
<tr>
<th>Subject</th>
<th>Age (yr)</th>
<th>Sex (M/F)</th>
<th>Height (cm)</th>
<th>Wt (kg)</th>
<th>TG (mg/dl)</th>
<th>TC (mg/dl)</th>
<th>VLDL-C (mg/dl)</th>
<th>LDL-C (mg/dl)</th>
<th>HDL-C (mg/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>54</td>
<td>M</td>
<td>188</td>
<td>128</td>
<td>1,207</td>
<td>348</td>
<td>288</td>
<td>75</td>
<td>28</td>
</tr>
<tr>
<td>2</td>
<td>41</td>
<td>F</td>
<td>166</td>
<td>66</td>
<td>1,413</td>
<td>280</td>
<td>190</td>
<td>32</td>
<td>16</td>
</tr>
<tr>
<td>3</td>
<td>54</td>
<td>F</td>
<td>164</td>
<td>49</td>
<td>3,648</td>
<td>729</td>
<td>672</td>
<td>49</td>
<td>24</td>
</tr>
<tr>
<td>4</td>
<td>62</td>
<td>F</td>
<td>166</td>
<td>65</td>
<td>694</td>
<td>319</td>
<td>199</td>
<td>83</td>
<td>37</td>
</tr>
<tr>
<td>5</td>
<td>29</td>
<td>M</td>
<td>173</td>
<td>69</td>
<td>754</td>
<td>220</td>
<td>119</td>
<td>91</td>
<td>25</td>
</tr>
<tr>
<td>6</td>
<td>44</td>
<td>M</td>
<td>182</td>
<td>82</td>
<td>475</td>
<td>239</td>
<td>85</td>
<td>123</td>
<td>32</td>
</tr>
<tr>
<td>7</td>
<td>44</td>
<td>F</td>
<td>178</td>
<td>61</td>
<td>143</td>
<td>239</td>
<td>29</td>
<td>125</td>
<td>85</td>
</tr>
<tr>
<td>8</td>
<td>28</td>
<td>F</td>
<td>165</td>
<td>52</td>
<td>90</td>
<td>176</td>
<td>18</td>
<td>95</td>
<td>63</td>
</tr>
<tr>
<td>9</td>
<td>26</td>
<td>F</td>
<td>170</td>
<td>61</td>
<td>76</td>
<td>181</td>
<td>15</td>
<td>111</td>
<td>55</td>
</tr>
<tr>
<td>10</td>
<td>35</td>
<td>M</td>
<td>170</td>
<td>69</td>
<td>75</td>
<td>219</td>
<td>19</td>
<td>158</td>
<td>42</td>
</tr>
<tr>
<td>11</td>
<td>34</td>
<td>M</td>
<td>173</td>
<td>66</td>
<td>103</td>
<td>168</td>
<td>21</td>
<td>109</td>
<td>38</td>
</tr>
<tr>
<td>12</td>
<td>38</td>
<td>M</td>
<td>168</td>
<td>71</td>
<td>232</td>
<td>190</td>
<td>46</td>
<td>91</td>
<td>53</td>
</tr>
</tbody>
</table>

TG, triglycerides; TC, total cholesterol; VLDL-C, LDL-C, and HDL-C, cholesterol in respective lipoproteins.
Monoclonal antibodies were coupled to CNBr-activated Sepharose (Pharmacia Fine Chemicals, Piscataway, NJ) according to the directions of the manufacturer. Specifically, IgG from 2.5 ml of ascites fluid (antibody 2b) was precipitated with 50% (NH₄)₂SO₄. The precipitate was dissolved in protein coupling buffer (0.1 M NaHCO₃, 0.5 M NaCl, pH 8.3) and incubated with ~3.5 ml of CNBr-activated Sepharose gel for 2 h at room temperature with gentle shaking. Remaining active groups on the gel were blocked with 1 M ethanolamine, pH 8.0, for 2 h at room temperature. The gel was washed with 0.1 M sodium acetate buffer, pH 4.0, and coupling buffer alternatively to remove excess absorbed protein. The gel was finally washed with 0.01 M phosphate-buffered saline (PBS), pH 7.2, buffer and stored in the same buffer containing antibiotics at 4°C.

Radioiodinated lipoproteins (2.5 × 10⁵ cpm, 20–50 μg total protein) were loaded onto the column in 3% BSA-PBS, pH 7.2, and left at 4°C overnight. The column was then eluted and washed with several gel bed volumes of PBS. 2-ml fractions were collected. Specifically bound proteins were eluted with 6 M thiocyanate, 10 mm Tris, pH 7.2, followed by regeneration of the column with extensive washings with PBS. Aliquots of column fractions were counted for ¹²⁵I-radioactivity.

Results

Stimulation of cholesterol esterification by various VLDL preparations. Initially, the abilities of various VLDL (d < 1.006) preparations isolated from normolipidemic and hyperlipidemic subjects to esterify cholesterol with [³H]oleate were examined. At equivalent VLDL protein concentrations (25 μg/ml) in the medium, HTG-VLDL stimulated esterification more effectively than normal VLDL. The values were 2.03±0.41 and 0.50±0.12 nmol cholesteryl ester formed per milligram cell protein per 18 h for HTG-VLDL (subjects 1–4) and normal VLDL (subjects 7–12), respectively (P < 0.001). HTG-VLDL also contained more cholesterol per mass of protein (cholesterol/protein ratios were 1.63±0.25 vs. 0.88±0.34 for HTG and normal VLDL, respectively (P < 0.01). A positive correlation (r = 0.81) was obtained between nanomoles of cholesterol esterified and the lipoprotein cholesterol/protein ratio for the four HTG and five normolipidemic VLDLs added at equivalent protein doses. In one experiment, the apo B/apo E ratios were determined by scanning densitometry after electrophoresis of the HTG and normal VLDL protein on 3–20% polyacrylamide gels. The HTG-VLDL contained proportionately more apo E than normal VLDL, and apo B/apo E ratios were 2.4±1.5 vs. 5.0±1.2, respectively, P < 0.01. Interestingly, the cholesterol esterification rate was inversely correlated with the VLDL apo B/apo E ratio (r = −0.77, n = 8). These results are compatible with those reported by Gianturco et al. (1) and suggest that HTG-VLDL in general are more potent in stimulating cholesterol esterification than are normal VLDL, and that apo E may be important in mediating the interaction of lipoproteins with cells. However, these experiments did not explain whether differences between HTG-VLDL and normal VLDL may be due to differences in the size and/or density distributions of VLDL subpopulations. Therefore, VLDL subfractions were examined.

Inhibition by anti-apo B antibodies and Fab fragments of the interaction of VLDL subfractions and LDL with cultured human fibroblasts. To ascertain the antibody dosage required to obtain maximum inhibition, increasing amounts of antibody 2b were added to dishes containing 25 μg/ml of each VLDL subfraction and of LDL (Fig. 2). Maximum inhibition was achieved at 10 μg/ml of antibody for all VLDL and LDL.

Human fibroblast cultures. Monolayer cultures of normal human skin fibroblasts were grown and maintained as previously described (32, 33). ~7.5–10.0 × 10⁶ cells were seeded into 35 × 15-mm dishes (Costar, Cambridge, MA) with Eagle's Modified Essential Medium (15% newborn calf serum). After 5 days, the cells were washed with saline and the medium was replaced with medium containing 10% lipoprotein-deficient human serum for 48 h.

Binding and degradation studies. Fibroblasts were grown in dishes as described above and experiments begun after growth for 48 h in the medium containing lipoprotein-deficient serum. Experiments with antibodies were conducted in two ways. In some experiments, the medium was removed from each cell dish and replaced with medium containing the indicated amounts of purified antibodies, followed 5 min later by ¹²⁵I-labeled lipoproteins (VLDL₁, VLDL₂, VLDL₃, or LDL) (18). Alternatively, lipoproteins were incubated with the indicated concentrations of purified antibodies for 30 min at 37°C before being added to the cells. Incubations of lipoproteins with cells were carried out at 37°C for 4 h in duplicate or triplicate dishes. The proteolytic degradation of ¹²⁵I-labeled lipoproteins by the fibroblasts was determined by measuring the TCA-soluble material in the spent medium after removal of free iodide with chloroform (32, 33). At the end of the incubations, the cells were washed as described (33), dissolved in 0.1 M sodium hydroxide, and aliquots were taken for determination of cell protein and cell-associated radioactivity (binding). Nonspecific degradation in the absence of cells was determined in no-cell control dishes that had been precoated with the incubation medium. Binding and degradation were also determined in the presence of 20-fold excesses of nonlabeled homologous lipoproteins. 20-fold of nonlabeled LDL also were added together with the different ¹²⁵I-labeled lipoprotein fractions in some experiments. Results are expressed as nanograms of ¹²⁵I-labeled lipoprotein bound or degraded per milligram of cell protein. In one experiment, various nonlabeled lipoproteins were assessed for their abilities to compete with ¹²⁵I-labeled LDL for binding to the fibroblasts at 4°C. Experiments were essentially carried out as described above with the medium containing 25 mm Hepes as buffering agent. Increasing concentrations of nonlabeled lipoproteins were added to the cells followed 5 min later by ¹²⁵I-labeled lipoproteins.

Incorporation of [³H]oleate into cellular cholesterol ester. Indicated concentrations of lipoproteins were incubated with cultured fibroblasts for 5 h before the addition of [³H]oleic acid (0.14 mM, 20–40 cpm/pmol) bound to defatted bovine serum albumin (BSA). After an additional 18 h, the cells were washed three times with saline, scrapped off the dishes, and aliquots were taken for protein determination. The concentration of intracellular cholesterol [³H]oleate was determined by thin layer chromatography as described (34, 35).

Chromatography of VLDL on monoclonal antibody affinity column.

Figure 1. Apo B of VLDL preparations analyzed by 3-10% polyacrylamide gradient gel electrophoresis and stained with Coo massie Blue. Lanes from left to right are: 1, LDL; 2, VLDL₁; 3, VLDL₂; and 4, VLDL₃ of HTG subject 5; 5, VLDL (d < 1.006) of control subject 10; 6 and 7, VLDL of two subjects with type III (E₅/E₅) hyperlipoproteinemia (shown for comparison); 8, VLDL (d < 1.006) of HTG subject 4.

Apoproteins B and E in Cell Binding of Very Low Density Lipoproteins
fractions. Antibody 2b inhibited LDL-stimulated cholesterol esterification by ~90% (18). VLDL-stimulated esterification was not inhibited, while stimulation by VLDL3 was inhibited by 70%. In agreement with the above, when in other experiments 10–25 μg/ml of lipoprotein proteins were incubated with 25 and 50 μg/ml of antibodies 2a, 2b, or Fab fragments of 2a (to ensure saturation of antibody binding sites on the lipoprotein particles), the binding and degradation by normal human fibroblasts of 125I-VLDL1, 125I-VLDL2, 125I-VLDL3, and 125I-LDL were inhibited least for 125I-VLDL1 and most for 125I-LDL (Table II and Fig. 3). The same antibodies and Fab fragments also inhibited cholesterol esterification dependent on VLDL3 by 35–73%, on VLDL2 by <5–32%, and on VLDL1 by <5–12% (Table II). The action of whole VLDL was inhibited by 33%. Preincubations of antibody with lipoproteins for 30 min yielded the same results as when no premixing or 5 min of premixing were employed. These results suggest that the lipoproteins were saturated with antibodies or Fab under the experimental conditions employed, i.e., that any lack of antibody-induced inhibition of lipoprotein-cell interactions was not due to lack of opportunity for maximal antibody-lipoprotein interaction. Antibodies 1a and 6, which were previously shown (18) to be much less effective in inhibiting the cellular processing of 125I-LDL, were much less effective inhibitors here, too, with all lipoprotein fractions. The Ig fraction of nonimmune mouse serum did not inhibit at all.

Incubations of fibroblasts in the presence of normolipidemic lipoproteins and antibodies were also carried out (Fig. 4 A–C). Stimulation of cholesterol esterification by these VLDL subfractions was minimal (over the basal rates), suggesting that differences in size and/or density distributions between HTG-VLDL and normal VLDL did not account for the differences in their interactions with cells. However, VLDL3 tended to stimulate better than VLDL1 or VLDL2. This may be due to the presence of IDL in VLDL3 as shown by Gianturco et al. (1). Inhibiting effects of antibodies on the lipoprotein-dependent cholesterol esterification were difficult to discern in view of the low rates of stimulated esterification. However, where stimulation of esterification was appreciable (Fig. 4 B), antibody 2b demonstrated inhibition similar to that observed for HTG-VLDL1.

Inhibition by homologous VLDL subfractions and by LDL of the cellular interactions of 125I-VLDL subfractions and of 125I-LDL. Each VLDL subfraction was able to inhibit the cellular degradation of its labeled homologue (Table III). Inhibition in the presence of 20-fold excesses of nonlabeled VLDL subfraction ranged from 40 to 64% (Table III). The relatively poorer ability of unlabeled VLDL1 to inhibit 125I-

Table II. Inhibition by Antibodies of Lipoprotein Dependent Cholesterol Esterification

<table>
<thead>
<tr>
<th>Added lipoprotein</th>
<th>Experiment 1</th>
<th>Experiment 2</th>
<th>Experiment 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Aby 2b</td>
<td>Fab 2a</td>
<td>Irr</td>
</tr>
<tr>
<td>VLDL1</td>
<td>&lt;5</td>
<td>12</td>
<td>&lt;5</td>
</tr>
<tr>
<td>VLDL2</td>
<td>&lt;3</td>
<td>&lt;5</td>
<td>&lt;5</td>
</tr>
<tr>
<td>VLDL3</td>
<td>73</td>
<td>54</td>
<td>&lt;5</td>
</tr>
<tr>
<td>Whole VLDL</td>
<td>—</td>
<td>—</td>
<td>3</td>
</tr>
<tr>
<td>LDL</td>
<td>86</td>
<td>92</td>
<td>&lt;5</td>
</tr>
</tbody>
</table>

Basal esterification ([3H]oleate → CE) in the absence of lipoproteins was 0.45±0.05 (Experiment 1, n = 5); 1.00±0.18 (Experiment 2, n = 4); and 0.27±0.05 (Experiment 3, n = 12) nmol/mg protein/18 h (mean±SD). Control rates in the presence of 25 μg/ml VLDL1, VLDL2, VLDL3, or LDL (subject 5), respectively, were 1.24, 1.08, 1.39, and 10.3 (Experiment 1), and 1.31, 1.05, 1.55, and 10.8 (Experiment 3). Rates in the presence of 25 μg/ml whole VLDL or LDL were 2.1 and 5.5 for Experiment 2. Basal rates have been subtracted from control rates to obtain uninhibited rates. Results are given as mean percent reduction of uninhibited rates produced by 25 and 50 μg of antibody 2b or 8.3 μg and 16.7 μg/ml Fab of antibody 2a. The two doses each gave similar degrees of inhibition. In Experiment 1, antibodies 2b, Fab 2a, or Irr were added to cells 5 min before addition of lipoproteins. In Experiments 2 and 3, antibodies 2b, 6, and 2a were preincubated with lipoproteins for 30 min at 37°C before the mixture was added to the cell dishes. Each point was performed in duplicate dishes. Coefficients of variation were <12%.

* Aby, antibody.
† Irr, a nonimmune mouse IgG fraction purified on Staphylococcal Protein-A Sepharose CL4B, added at equivalent concentrations.

Figure 2. Inhibition by monoclonal anti-apo B antibody 2b of lipoprotein-dependent esterification of cholesterol in cultured human fibroblasts. Lipoproteins were isolated from the plasma of HTG subject 5 and VLDL subfractions were prepared by zonal ultracentrifugation. Increasing doses of antibody 2b were incubated with 25 μg/ml of lipoprotein for 30 min at 37°C before being added to the cells. The basal rate of cholesterol esterification (CE) for the fibroblasts was 0.27±0.05 nmol CE/mg cell protein/18 h. Net uninhibited esterification rates for VLDL1, VLDL2, and LDL were 1.32, 1.56, and 10.8 nmol CE/mg cell protein/18 h, respectively. Mean coefficient of variation was 12% for each point in duplicate dishes. — o —, VLDL1; — △ —, VLDL2; — ■ —, LDL.

Figure 3. Inhibition of binding and degradation of 125I-labeled HTG-VLDL1, VLDL2, and VLDL3 (each at 10 μg/ml medium) and of 125I-LDL (5 μg/ml) by antibody 2a in cultures of human fibroblasts. Lipoproteins were isolated from the plasma of subject 6 and VLDL subfractions were prepared by zonal ultracentrifugation. Respective 100% values (nanograms per milligram of cell protein) for binding were 121, 122, 215, and 187, and for degradation were 525, 224, 488, and 631 for VLDL1, and LDL, respectively. Mean coefficient of variation was <8% for duplicate dishes.
Figure 4. Effect of addition of monoclonal anti-apo B and anti-apo E antibodies on normolipidemic lipoprotein-dependent esterification of cholesterol in cultured human fibroblasts.

VLDL degradation is probably due to an exchange of radiolabeled apoproteins between the tracer and cold VLDL (16). As the percentage of TMU-soluble apoproteins decreases, i.e., VLDL2 → VLDL3 (22), the potential for exchange would diminish and could account for the increasing inhibiting effect of unlabeled VLDL2 and VLDL3 on VLDL exchange.

In contrast with unlabeled VLDL used as inhibitors, 20-fold excess of unlabeled LDL inhibited 125I-VLDL by <5%, 125I-VLDL2 by only 9–27%, and 125I-VLDL3 by only 24–47%, while LDL inhibited the degradation of 125I-LDL by ~90%. Thus, the patterns of inhibition produced by antibodies 2a, 2b, and Fab fragments were similar to the patterns produced by excess unlabeled LDL.

To document that the VLDL cell interactions were occurring at the cellular LDL (apo B,E)-receptor, 125I-LDLs were incubated at 4°C in the presence of competing nonlabeled LDL and VLDL (Table IV). VLDL and LDL were equally potent, on a protein mass basis, in competing against 125I-LDL for occupancy of the LDL receptor, suggesting that the VLDL-cell interactions indeed were occurring at that receptor.

Immunoaffinity chromatography. In previous work using monoclonal antibodies 2a or 2b, the relative potencies of VLDL subfractions and LDL in competing against 125I-LDL for antibody binding was assessed in solid-phase plate assays (36). Competitive abilities of VLDL were inversely related to their sizes, i.e., LDL > VLDL3 > VLDL2 > VLDL1. To confirm the results obtained with VLDL subfractions in the competitive RIAs, the VLDL subfractions and LDL of donor

Table IV. Competition for Binding of 125I-LDL to Human Fibroblasts

<table>
<thead>
<tr>
<th>Lipoprotein competitor</th>
<th>Cell associated</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg/ml</td>
<td>ng/mg cell protein</td>
</tr>
<tr>
<td>0</td>
<td>129</td>
</tr>
<tr>
<td>FH-LDL</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>95</td>
</tr>
<tr>
<td>10</td>
<td>71</td>
</tr>
<tr>
<td>25</td>
<td>66</td>
</tr>
<tr>
<td>100</td>
<td>40</td>
</tr>
<tr>
<td>200</td>
<td>24</td>
</tr>
<tr>
<td>Subject 4-VLDL</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>103</td>
</tr>
<tr>
<td>25</td>
<td>64</td>
</tr>
<tr>
<td>100</td>
<td>41</td>
</tr>
</tbody>
</table>
Table V. Binding of $^{125}$I-Lipoproteins to an Anti-LDL Immunoaffinity Column

<table>
<thead>
<tr>
<th>$^{125}$I-ligands</th>
<th>Counts bound to column</th>
<th>Counts precipitable by TMU</th>
</tr>
</thead>
<tbody>
<tr>
<td>VLDL ($d &lt; 1.006$)</td>
<td>34</td>
<td>50</td>
</tr>
<tr>
<td>VLDL$_1$</td>
<td>23</td>
<td>37</td>
</tr>
<tr>
<td>VLDL$_2$</td>
<td>42</td>
<td>49</td>
</tr>
<tr>
<td>VLDL$_3$</td>
<td>53</td>
<td>69</td>
</tr>
<tr>
<td>LDL</td>
<td>96</td>
<td>97</td>
</tr>
<tr>
<td>HDL</td>
<td>&lt;0.5</td>
<td>&lt;0.1</td>
</tr>
</tbody>
</table>

$\sim 2.5 \times 10^6$ of $^{125}$I-labeled lipoprotein (10–25 µg protein) of donor 5 were loaded in 3% BSA-PBS buffer, pH 7.4, onto an immunoaffinity column containing monoclonal anti LDL antibody 2b coupled to Sepharose 4B.

5 were iodinated and subjected to affinity chromatography on a column containing antibody 2b (Table V). 23% of VLDL$_1$, 53% of VLDL$_3$, and 34% of the whole VLDL ($d < 1.006$) were bound. In control experiments, iodinated HDL was passed through the same column, and the $^{125}$I-VLDL fractions and $^{125}$I-HDL were also passed through a column containing no antibodies. Virtually all of $^{125}$I-LDL, but none of $^{125}$I-HDL, were bound to the antibody-containing column. <1.0% of any of the lipoproteins was retained on the control column. To ascertain that there was no selective retention of apo B on the column, the proportion of TMU-precipitable counts in the starting whole $^{125}$I-VLDL and in nonbound $^{125}$I-VLDL fractions were compared. They were found to be indistinguishable (50 and 53%, respectively), suggesting that the apo B and non-apo B proteins of VLDL were not dissociated on the column. The retention of VLDL fractions by the column was similar to the rank order of competition potencies of the fractions in the competitive immunoassays. Also, the inhibition by antibody 2b of VLDL-dependent cholesterol esterification was compatible with the affinity column data (Table II). The data strongly suggest that the expression of the 2a and 2b epitopes on VLDL is inversely related to VLDL size.

**Inhibition by anti-apo E antibodies of the interaction of VLDL and LDL fractions with cultured human fibroblasts.** Since a significant proportion of HTG-VLDL$_1$ and VLDL$_2$ cellular uptake could not be inhibited by anti-apo B antibodies 2a or 2b, it followed that other apolipoproteins on the surface of these lipoproteins could be responsible for binding to cells. Therefore, antibodies directed against apo E were tested for their abilities to block VLDL-cell interactions (Figs. 5 and 6). Polyclonal anti-apo E antiserum (R224-3) inhibited binding (not shown) and degradation of VLDL$_1$ by $\sim 25\%$ (Fig. 6), and VLDL$_1$-dependent cholesterol esterification by $\sim 45\%$ (Fig. 5). On the other hand, VLDL$_2$ was poorly inhibited if at all under the same conditions. Two anti-apo E monoclonal antibodies were even more effective inhibitors of VLDL$_1$-cell interactions (Figs. 5 and 6, B and C). These antibodies did not inhibit VLDL$_2$. Differences in apo E content of the VLDL fractions cannot account for the difference in antibody inhibition (Fig. 6), since VLDL$_1$ generally has less apo E than VLDL$_1$ and therefore antibody was clearly in excess. A third monoclonal anti-apo E antibody, 1363 C3A10, did not prevent cellular uptake and processing of either normolipidemic (Fig. 4 D) or HTG-VLDL$_3$ subfractions (Figs. 5 D and 6 D). Six other monoclonal IgM anti-apo E antibodies also were equally ineffective in inhibiting VLDL$_2$ uptake (not shown).

Interestingly, in several cases the anti-apo E antibodies seemed to enhance the cellular processing of the HTG-VLDL$_3$ (Figs. 5 and 6). This effect may be due to a conformational change in the lipoprotein structure induced by antibody-binding to a determinant distant from the cellular recognition site (cooperativity) such that cellular uptake is enhanced. Another explanation of the enhanced uptake is the possible interaction of the antibody-VLDL$_3$ immune complex with a purported Fc receptor on human fibroblast (37). As the Fc receptor binds aggregated IgG or immune complexes preferentially over monomeric IgG, this may explain the increased stimulation of VLDL$_3$ uptake at higher antibody/antigen ratios (Figs. 5 and 6).

![Figure 5](image_url)
Figure 6. Inhibition by polyclonal or monoclonal anti-apo E antibodies of the degradation of $^{125}$I-lipoproteins by cultured human fibroblasts. VLDL subfractions were isolated from HTG subjects 5 (A–C) or 4 (D) and iodinated as described in Methods. Indicated doses of antibodies were incubated with 25 $\mu$g/ml of $^{125}$I-VLDL$_3$ or $^{125}$I-VLDL$_1$ for 30 min at 37°C before being added to the cells. 100% values (nanograms per milligram of cell protein, 4 h) for degradation of VLDL$_{A-C}$ and VLDL$_{A-C}$ were 186 and 99 for $A-C$ and 745 and 68 for $D$. Mean coefficients of variation were 14% ($A-C$) and 8% ($B$) for points determined in duplicate dishes. The antibodies used are described in the legend to Fig. 5. VLDL-apo E contents were determined by conventional RIA. For VLDL, and VLDL$_3$ in $A-C$, apo E was 3.2% and 1.2% of total VLDL protein. In $D$ the values were 8.9% and 2.7%.

Discussion

Triglyceride-rich lipoproteins isolated from plasma are bound, internalized, and degraded by cultured fibroblasts and aortic smooth muscle cells via the LDL (apo B,E) receptor in a metabolic sequence that resembles the cellular processing of LDL (38). But not all VLDL or chylomicrons isolated from plasma seem to be taken up at identical rates. Chylomicrons and large VLDL particles are taken up more slowly than the smaller chylomicrons or VLDL remnants produced by lipoprotein lipase catalyzed lipolysis (17, 39). Larger $\alpha$-migrating VLDL isolated from plasmas of subjects with various forms of hypertriglyceridemia are taken up much more rapidly than seemingly similar $\alpha$-VLDL particles isolated under identical conditions from normal plasma (2, 16). $\beta$-VLDL induced by high fat, high carbohydrate diets are processed more rapidly than $\alpha$-VLDL (38). Presumably, all of these lipoprotein-cell interactions are mediated by apoproteins, but the alterations in lipoprotein-apoprotein structure responsible for the differences are not known.

Four general approaches have been used to ascertain which apoproteins play roles in the recognition of lipoproteins by cellular receptors; a) studies of interactions of apoprotein-lipid recombinants with cultured cells or perfused organs, b) studies of effects of alterations of compositions of hololipoproteins on cell interactions, c) studies of consequences of cleavage of apoproteins in lipoproteins on cell interactions, and d) studies relating immunologic activities of apoproteins to cellular binding. The role of apo E in cell binding was recognized in experiments with apo E-phospholipid recombinants using both wild type (E$_3$) and mutant (E$_2$) forms of the protein (9-11). The compositional approach provided information on the opposing roles of apo E and apolipoprotein CIII in VLDL binding (40, 41). Thrombin-induced cleavage of apo E abolished the binding of large HTG-VLDL$_1$ to fibroblasts, implying that apo E mediates the interactions (16). The immunologic approach uncovered that the size of VLDL affects the dispositions of apo B on the surfaces of lipoproteins (17, 42-46) and also that the cellular binding of LDL can be inhibited only by selected monoclonal anti-LDL antibodies, i.e., many antibodies did not inhibit (17, 18, 42). Therefore, it was possible to connect single epitopes of LDL with cellular binding.

In the present experiments, each of the HTG $^{125}$I-VLDL subfractions was appreciably taken up and degraded by the cultured normal fibroblasts, and each fraction also stimulated the esterification of [H]oleate into cholesteryl-esters. Normal VLDL interacted much less effectively with cells. Antibodies 2a and 2b and Fab 2a inhibited these processes in a progressive fashion, with inhibition increasing from VLDL$_1$ to VLDL$_2$ to VLDL$_3$, and finally to LDL. A similar pattern of inhibition was produced by excess LDL. Antibodies 1a or 6 produced much less inhibition, and nonimmune mouse IgG produced none at all. Therefore, the inhibition by antibodies 2a and 2b was specific. The ability of Fab 2a at equimolar doses to produce similar degrees of inhibition further confirms the specificity of the inhibition. Since lower doses of the inhibiting antibodies and Fab fragments than were used for most experiments were shown to inhibit to the same extent (Fig. 2), all available epitopes must have been saturated, yet some proportion of each VLDL subfraction was still taken up by the cells. If epitopes 2a and 2b are involved in cellular recognition and for the reasons enumerated in the Introduction, we believe they are, cellular recognition of VLDL must have occurred not only via apo B, but also at alternate domains, probably on apo E. This hypothesis was tested by incubating lipoproteins before their addition to cells with anti-apo E antibodies. The experiments clearly showed a preferential inhibition of VLDL$_1$ uptake and cellular processing by these antibodies when compared with the smallest VLDL$_3$ fraction. From the data, it seems that the size heterogeneity introduced either during VLDL catabolism (47) or during secretion of nascent VLDL particles (48) is accompanied by heterogeneity of cell binding characteristics. While the vast majority of the largest VLDL$_1$ particles interacts with the apo B,E-receptor almost solely via apo E, a progressively larger proportion of the smaller particles of VLDL$_2$ and VLDL$_3$ interact via apo B, and the end product of the "cascade," LDL, interacts almost completely via apo B. Similar conclusions based on thrombin-induced proteolysis of apo E in VLDL subfractions have been reported in abstract form (49).

What accounts for the initial preference for apo E and the gradual changeover to apo B? Several possibilities exist. The relevant binding sites on apo B may not be available on the largest VLDL, either because they are buried in lipid or are masked by other apoproteins. Alternatively, perhaps the domains are not masked, but the organization of apo B in larger VLDL is such that the appropriate domains interact with cellular receptors very weakly. The experiments in which the inhibition of $^{125}$I-lipoprotein binding to antibody 2a, but not to antibody 1a, varied inversely with the flotation rate of VLDL (Table III), demonstrated that the expression of relevant regions of apo B vary with VLDL size and/or density. These
results support the hypothesis that the disposition of apo B may play a role in the interaction of VLDL with cells. However, these experimental results do not distinguish whether the relevant domain is buried or weakly reactive for other reasons. Another possibility for the gradual changeover from apo E to apo B may be simply that there are more molecules of apo E per particle on large than on small VLDL, and virtually none on LDL. This idea is supported by the observation that apo E contents of VLDL tend to be higher than those for VLDL (Krul, E. S., M. J. Tikkanen, and G. Schonfeld, manuscript in preparation) (Fig. 6), and by the direct relationship between binding of phospholipid vesicles to fibroblasts and the amounts of functional apo E associated with the vesicles (10, 11). The effective interactions of HTG-VLDL with cells and the lack of such interactions by normal VLDL, also may be due to the presence of greater amounts of apo E on the former (50–52). A third alternative is that the conformation of apo E in VLDL favors cellular interaction but apo E conformations may change during lipolysis and catabolism of VLDL in an unfavorable direction. These three alternatives are not mutually exclusive, and one or more of them may be operating at the same time, but more work is needed to ascertain which are operative and to what extent.

Acknowledgments

The authors would like to thank Ratna Dargar and Barbara Pfleger for technical assistance, and Lois Weismantle of the Lipid Research Clinic for obtaining the blood donors. The typing of this manuscript by Phyllis Anderson is appreciated.

This work was supported by National Institutes of Health grant HL 15308 and the Mallinckrodt Hybridoma Contract. Dr. Krul is the recipient of a Fellowship of the Medical Research Council of Canada. Dr. Tikkanen was supported in part by a Fogarty International Fellowship, National Institutes of Health.

References


